Literature DB >> 26648627

Prescribing azithromycin.

Brendan J McMullan1, Mona Mostaghim1.   

Abstract

Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and excellent tissue penetration. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used in preference to other macrolides for some sexually transmitted and enteric infections. Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. Potential major adverse effects include cardiovascular arrhythmias and hearing loss. Macrolide resistance is also a problem, as are interactions with commonly prescribed drugs.

Entities:  

Keywords:  antibiotic resistance; azithromycin; immunomodulators; macrolide antibiotics

Year:  2015        PMID： 26648627      PMCID： PMC4653965          DOI： 10.18773/austprescr.2015.030

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


  24 in total

1.  The structures of four macrolide antibiotics bound to the large ribosomal subunit.

Authors:  Jeffrey L Hansen; Joseph A Ippolito; Nenad Ban; Poul Nissen; Peter B Moore; Thomas A Steitz
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

2.  Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin.

Authors:  N P Beckey; D Parra; A Colon
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

3.  Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.

Authors:  D C L Lam; B Lam; M K Y Wong; C Lu; W Y Au; E W C Tse; A Y H Leung; Y L Kwong; R H S Liang; W K Lam; M S M Ip; A K W Lie
Journal:  Bone Marrow Transplant       Date:  2011-02-14       Impact factor: 5.483

Review 4.  Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin.

Authors:  Kari A Mergenhagen; Pamela M Olbrych; Arun Mattappallil; Michael P Krajewski; Michael C Ott
Journal:  Clin Ther       Date:  2013-02-28       Impact factor: 3.393

Review 5.  Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline.

Authors:  Jerry M Zuckerman; Fozia Qamar; Bartholomew R Bono
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

6.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

Authors:  Josje Altenburg; Casper S de Graaff; Ymkje Stienstra; Jacobus H Sloos; Eric H J van Haren; Ralph J H Koppers; Tjip S van der Werf; Wim G Boersma
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Catherine A Byrnes; Keith Grimwood; Paul J Torzillo; Paul A Bauert; I Brent Masters; Abbey Diaz; Gabrielle B McCallum; Charmaine Mobberley; Irene Tjhung; Kim M Hare; Robert S Ware; Anne B Chang
Journal:  Lancet Respir Med       Date:  2013-09-17       Impact factor: 30.700

Review 8.  Macrolide antibiotics for cystic fibrosis.

Authors:  Kevin W Southern; Pierre M Barker; Arturo Solis-Moya; Latifa Patel
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

9.  Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin.

Authors:  Paul Mick; Brian D Westerberg
Journal:  J Otolaryngol       Date:  2007-10

Review 10.  The role of macrolides in asthma: current evidence and future directions.

Authors:  Ernie H C Wong; James D Porter; Michael R Edwards; Sebastian L Johnston
Journal:  Lancet Respir Med       Date:  2014-06-16       Impact factor: 30.700
View more
  21 in total

1.  Gut Microbial Diversity in Antibiotic-Naive Children After Systemic Antibiotic Exposure: A Randomized Controlled Trial.

Authors:  Thuy Doan; Ahmed M Arzika; Kathryn J Ray; Sun Y Cotter; Jessica Kim; Ramatou Maliki; Lina Zhong; Zhaoxia Zhou; Travis C Porco; Benjamin Vanderschelden; Jeremy D Keenan; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

2.  Risk factors for campylobacteriosis in Australia: outcomes of a 2018-2019 case-control study.

Authors:  Danielle M Cribb; Liana Varrone; Rhiannon L Wallace; Angus T McLure; James J Smith; Russell J Stafford; Dieter M Bulach; Linda A Selvey; Simon M Firestone; Nigel P French; Mary Valcanis; Emily J Fearnley; Timothy S Sloan-Gardner; Trudy Graham; Kathryn Glass; Martyn D Kirk
Journal:  BMC Infect Dis       Date:  2022-06-30       Impact factor: 3.667

Review 3.  Mechanism of action, resistance, synergism, and clinical implications of azithromycin.

Authors:  Mohsen Heidary; Ahmad Ebrahimi Samangani; Abolfazl Kargari; Aliakbar Kiani Nejad; Ilya Yashmi; Moloudsadat Motahar; Elahe Taki; Saeed Khoshnood
Journal:  J Clin Lab Anal       Date:  2022-04-21       Impact factor: 3.124

4.  In Vitro Evaluation of the Antimicrobial Ability and Cytotoxicity on Two Melanoma Cell Lines of a Benzylamide Derivative of Maslinic Acid.

Authors:  Ioana Zinuca Pavel; Corina Danciu; Camelia Oprean; Cristina Adriana Dehelean; Delia Muntean; René Csuk; Danina Mirela Muntean
Journal:  Anal Cell Pathol (Amst)       Date:  2016-12-05       Impact factor: 2.916

5.  Bradycardia and Hypothermia Complicating Azithromycin Treatment.

Authors:  Kerri Benn; Sam Salman; Madhu Page-Sharp; Timothy M E Davis; Jim P Buttery
Journal:  Am J Case Rep       Date:  2017-08-11

6.  A case of pulmonary infection due to Mycobacterium paraffinicum from the Amazon Region.

Authors:  Adriana Rodrigues Barretto; José Tadeu Colares Monteiro; Maria Luiza Lopes; Ana Roberta Fusco da Costa
Journal:  IDCases       Date:  2017-07-12

7.  Mass Azithromycin Distribution and Community Microbiome: A Cluster-Randomized Trial.

Authors:  Thuy Doan; Armin Hinterwirth; Ahmed M Arzika; Sun Y Cotter; Kathryn J Ray; Kieran S O'Brien; Lina Zhong; Eric D Chow; Zhaoxia Zhou; Susie L Cummings; Dionna Fry; Catherine E Oldenburg; Lee Worden; Travis C Porco; Jeremy D Keenan; Thomas M Lietman
Journal:  Open Forum Infect Dis       Date:  2018-07-24       Impact factor: 3.835

Review 8.  The COVID-19 pandemic: a threat to antimicrobial resistance containment.

Authors:  Raspail C Founou; Ariel J Blocker; Michel Noubom; Cedrice Tsayem; Siméon P Choukem; Maarten Van Dongen; Luria L Founou
Journal:  Future Sci OA       Date:  2021-06-10

Review 9.  An eye for azithromycin: review of the literature.

Authors:  Kostas A Kagkelaris; Olga E Makri; Constantine D Georgakopoulos; George D Panayiotakopoulos
Journal:  Ther Adv Ophthalmol       Date:  2018-07-30

Review 10.  Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.

Authors:  Rami A Al-Horani; Srabani Kar; Kholoud F Aliter
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.